PE20151323A1 - METADOXINE FOR USE IN THE TREATMENT OF HEPATIC DISEASES AND PROLONGED-RELEASE FORMULATIONS OF METADOXINE - Google Patents

METADOXINE FOR USE IN THE TREATMENT OF HEPATIC DISEASES AND PROLONGED-RELEASE FORMULATIONS OF METADOXINE

Info

Publication number
PE20151323A1
PE20151323A1 PE2015000406A PE2015000406A PE20151323A1 PE 20151323 A1 PE20151323 A1 PE 20151323A1 PE 2015000406 A PE2015000406 A PE 2015000406A PE 2015000406 A PE2015000406 A PE 2015000406A PE 20151323 A1 PE20151323 A1 PE 20151323A1
Authority
PE
Peru
Prior art keywords
metadoxine
treatment
prolonged
release formulations
hepatic diseases
Prior art date
Application number
PE2015000406A
Other languages
Spanish (es)
Inventor
Gulik Frederick Van
Yamsani Madhusudan Rao
Shankar Bodapunti Prabha
Original Assignee
Eurodrug Lab B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Lab B V filed Critical Eurodrug Lab B V
Publication of PE20151323A1 publication Critical patent/PE20151323A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere una composicion farmaceutica que comprende 1000 mg a 1500 mg de metadoxina en combinacion con al menos un excipiente farmaceuticamente aceptable. La metadoxina se utiliza en la prevencion y en el tratamiento de la Enfermedad de Higado Graso No Alcoholica (NAFLD) y de la Esteatohepatitis No Alcoholica (NASH), en la mejora de la tasa de supervivencia de pacientes con Hepatitis Alcoholica SeveraThe invention relates to a pharmaceutical composition comprising 1000 mg to 1500 mg of metadoxine in combination with at least one pharmaceutically acceptable excipient. Metadoxin is used in the prevention and treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), in improving the survival rate of patients with Severe Alcoholic Hepatitis

PE2015000406A 2012-09-26 2013-01-22 METADOXINE FOR USE IN THE TREATMENT OF HEPATIC DISEASES AND PROLONGED-RELEASE FORMULATIONS OF METADOXINE PE20151323A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2012004028 2012-09-26

Publications (1)

Publication Number Publication Date
PE20151323A1 true PE20151323A1 (en) 2015-10-10

Family

ID=47018954

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000406A PE20151323A1 (en) 2012-09-26 2013-01-22 METADOXINE FOR USE IN THE TREATMENT OF HEPATIC DISEASES AND PROLONGED-RELEASE FORMULATIONS OF METADOXINE

Country Status (6)

Country Link
KR (1) KR20150063040A (en)
BR (1) BR112015006642B1 (en)
MX (1) MX2015003810A (en)
PE (1) PE20151323A1 (en)
PH (2) PH12015500353A1 (en)
WO (1) WO2014048511A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976970A (en) * 2014-06-06 2014-08-13 程奉平 Method for preparing metadoxine sustained release tablet

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301108C (en) * 2004-10-15 2007-02-21 山东齐都药业有限公司 Metaducine dispersion tablet and its preparation method
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
KR101697773B1 (en) * 2008-03-10 2017-01-18 유로드러그 레버러토리즈 비. 브이. Modified release composition comprising doxofylline
IT1393338B1 (en) * 2009-03-06 2012-04-20 Baldacci Lab Spa THERAPEUTIC USE OF METADOXINE AS AN INHIBITOR OF THE LIVER FIBROSIS.
EA023758B1 (en) * 2009-06-25 2016-07-29 Алкобра Лтд. Use of metadoxine for treating attention deficit/hyperactivity disorder (adhd/add)
WO2011061743A1 (en) * 2009-11-18 2011-05-26 Alcobra Ltd. Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders

Also Published As

Publication number Publication date
MX2015003810A (en) 2015-07-17
PH12016501553B1 (en) 2017-09-11
BR112015006642B1 (en) 2022-08-02
WO2014048511A1 (en) 2014-04-03
PH12015500353A1 (en) 2015-04-20
PH12016501553A1 (en) 2017-09-11
BR112015006642A2 (en) 2017-07-04
KR20150063040A (en) 2015-06-08

Similar Documents

Publication Publication Date Title
AR115939A2 (en) COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
WO2010121128A3 (en) Compositions and methods for treating or inhibiting liver injury
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
BR112014031394A2 (en) compositions and methods for transmucosal absorption
CO6400186A2 (en) ULIPRISTAL ACETATE TABLETS
MX346879B (en) Ready to use ketorolac formulations.
WO2013183062A3 (en) Palatable formulations of ibuprofen
MX2010010954A (en) Therapeutic for hepatic cancer.
PE20081789A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACLIDIN
AR091351A1 (en) BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING
MX347927B (en) Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease.
AR073265A1 (en) USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION OF ICTUS OR TRANSITIONAL ISCHEMICAL ATTACK
PE20131035A1 (en) NEVIRAPIN FORMULATION OF PROLONGED RELEASE
GT200600263A (en) DOSAGE REGIME FOR PRASUGREL
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
AR061233A1 (en) FORMULATION OF PROLONGED LIBERATION OF NALTREXONA
JO3587B1 (en) Oral dosage forms of bendamustine
AR065582A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
PE20151323A1 (en) METADOXINE FOR USE IN THE TREATMENT OF HEPATIC DISEASES AND PROLONGED-RELEASE FORMULATIONS OF METADOXINE
MX2010011193A (en) Liquid pharmaceutical composition for pain treatment and prevention.

Legal Events

Date Code Title Description
FC Refusal